Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsProtocol groupPlasma cell neoplasmsTransplantationDiseaseMultiple MyelomaStem Cell mobilizationStem Cell Transplantation, AutologousSubgroupICD10C90.-C90.0-Z94.80MeSHHematopoietic Stem Cell MobilizationMultiple MyelomaPlasmacytomaSequenceAURIGA: DRTM1800/LENA10, MM, maint. according to ASCT, C1-2 (PID2796) -|- C3-6 (PID2797) -|- C7+ (PID2798)IFM 2009/DETERMINATION: BORT1.3/LENA25/DEXA20, Ind., MM (PID1036) -|- cons. after ASCT (PID1040) or cons. without ASCT (PID1037) -|- maint. after ASCT (PID891) or maint. (PID2181)ChemotherapyChemo-substanceBortezomibCyclophosphamideDaratumumabDexamethasoneLenalidomideMelphalanChemo-substanceBortezomibCyclophosphamideDaratumumabDexamethasoneLenalidomideMelphalanChemo-substanceBortezomibCyclophosphamideDaratumumabDexamethasoneLenalidomideMelphalanChemo-substanceBortezomibCyclophosphamideDaratumumabDexamethasoneLenalidomideMelphalanNo. Substances123 RadiotherapySupportive therapySupportive substanceAcetylsalicylic acidAciclovirAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDalteparinDexamethasoneDimetindenFilgrastimFosaprepitantFurosemideGranisetronMesnaMontelukastPantoprazoleParacetamolPlerixaforPrednisoloneSupportive substanceAcetylsalicylic acidAciclovirAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDalteparinDexamethasoneDimetindenFilgrastimFosaprepitantFurosemideGranisetronMesnaMontelukastPantoprazoleParacetamolPlerixaforPrednisoloneSupportive substanceAcetylsalicylic acidAciclovirAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDalteparinDexamethasoneDimetindenFilgrastimFosaprepitantFurosemideGranisetronMesnaMontelukastPantoprazoleParacetamolPlerixaforPrednisoloneSupportive substanceAcetylsalicylic acidAciclovirAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDalteparinDexamethasoneDimetindenFilgrastimFosaprepitantFurosemideGranisetronMesnaMontelukastPantoprazoleParacetamolPlerixaforPrednisoloneNo. Substances4568Protocol classificationTherapy classificationalternativecurrent standardstudy analogIntensityhigh doseHigh dose myeloablativeStandard doseTherapy indicationFirst lineTherapy phaseconditioningConsolidationMaintenanceTherapy intentioncurativedisease controlRisksAnemia Hb below 8g/dlArthalgiaConstipationCOVID-19 infectionDiarrheaEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaHeadacheHypertensionHypokalemiaInfectionsLymphopeniaNeuropathyNeutropeniaPneumoniaRashThrombocytopenia below 50 000/µlThromboembolic EventUpper Respiratory Tract Infection only studiesPublicationAuthorAttal MBadros AZGoldschmidt HMcCarthy PRichardson PDiseaseMM Stadium II und III, 18 - 65 Jahre, ECOG 0-3 (3 nur wenn durch Myelom bedingt), ErstlinieMM Stadium II und III, 18-65 Jahre, ECOG 0-3, ErstlinieMultiples Myelom, ECOG 0-1multiples Myelom, Erstdiagnose nach Induktionstherapie und autologer Transplantation, ECOG 0-1multiples Myelom, nach Induktionstherapie und autologer Transplantation, VGPR, MRD+, ECOG 0-2neudiagnostiziertes multiples Myelom, < 65 JahreOriginBMT Program, Roswell Park Cancer Institute, Buffalo, NY, CALGB 100104German-Speaking Myeloma Multicenter Group (GMMG), Therapieteil analog der HD-3 StudieHOVON-65/GMMG-HD4 StudieIFm2009 / Determination trialInstitut Universitaire du Cancer de Toulouse-Oncopole and Service d’Epidémiologie, Toulouse, IFM 2009 StudyUniversity of Maryland, Baltimore, Maryland, United States, AURIGA studyProtocols in Revision 8 protocols foundProtocols under revision.Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 10, Multiple Myeloma, Consolidation after Autologous Stem Cell Transplantation. (PID1040 V1.2)Daratumumab 1800 / Lenalidomide 10, multiple myeloma, maintenance after Stem Cell Transplantation, Autologous, Cycle 1-2 (PID2796 V1.0)Daratumumab 1800 / Lenalidomide 10, multiple myeloma, maintenance after Stem Cell Transplantation, Autologous, Cycle 3-6 (PID2797 V1.0)Daratumumab 1800 / Lenalidomide 10, multiple myeloma, maintenance after Stem Cell Transplantation, Autologous, Cycle 7+ (PID2798 V1.0)High dose Cyclophosphamide 2000 for stem cell mobilization, Multiple Myeloma (PID535 V1.0.1)High-dose Melphalan 200 before Autologous Stem Cell Transplantation, Multiple Myeloma (PID528 V2.2)Lenalidomide 10, Multiple Myeloma, maintenance (PID2181 V1.0)Lenalidomide 10, Multiple Myeloma, Maintenance after Autologous Stem Cell Transplantation, Autologous (PID891 V1.1)
